Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Cash & Equivalents (2021 - 2025)

Rxo (RXO) has disclosed Cash & Equivalents for 5 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 51.43% year-over-year to $17.0 million, compared with a TTM value of $17.0 million through Dec 2025, down 51.43%, and an annual FY2025 reading of $17.0 million, down 51.43% over the prior year.
  • Cash & Equivalents was $17.0 million for Q4 2025 at Rxo, down from $25.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $187.0 million in Q3 2022 and bottomed at $5.0 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $56.5 million, with a median of $29.0 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents tumbled 94.9% in 2023, then soared 600.0% in 2024.
  • Year by year, Cash & Equivalents stood at $29.0 million in 2021, then soared by 237.93% to $98.0 million in 2022, then crashed by 94.9% to $5.0 million in 2023, then skyrocketed by 600.0% to $35.0 million in 2024, then crashed by 51.43% to $17.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for RXO at $17.0 million in Q4 2025, $25.0 million in Q3 2025, and $18.0 million in Q2 2025.